Stellantis is investing $13 billion to dramatically increase its U.S. vehicle production, creating a ripple effect across the domestic auto industry. This theme focuses on the American automotive suppliers and industrial companies poised to benefit from the automaker's major expansion.
Published on October 15
Stellantis' $13 billion commitment represents one of the largest automotive investments in recent U.S. history. This scale of expansion creates significant demand ripples throughout the supply chain.
When vehicle production increases by 50%, suppliers of parts, materials, and services see immediate demand growth. This group captures companies positioned right in that value chain.
This investment signals renewed confidence in U.S. manufacturing capabilities and could pressure other automakers to follow suit, creating even broader opportunities.
Stellantis' massive $13 billion investment to expand U.S. vehicle production by 50% creates a clear opportunity. When automakers dramatically increase manufacturing, the companies that supply parts, materials, and services directly benefit from higher demand. This represents a tactical play on strengthening the American automotive supply chain.
This group focuses on American automotive suppliers and industrial companies positioned along the vehicle production value chain. These range from component manufacturers to providers of factory automation and logistics services. The investment creates a ripple effect that could benefit multiple layers of the domestic auto industry.
Each company was selected based on their direct or indirect exposure to increased U.S. vehicle production. Professional analysts identified businesses that supply critical components, raw materials, or industrial services that would see higher demand from Stellantis' expansion and the broader strengthening of American automotive manufacturing.
Basket market capitalisation summary and investor takeaways.
F: $46.37B
GM: $54.41B
LEA: $5.31B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+7
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+133.22%
On average, analysts expect assets in this group to grow 133.22% over the next year.
13 of 17 assets in this group are rated Buy by professional analysts.
